AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Adenosine deaminase-like protein

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q6DHV7

UPID:

ADAL_HUMAN

Alternative names:

Adenosine deaminase-like protein isoform 1; N6-mAMP deaminase; N6-methyl-AMP aminohydrolase

Alternative UPACC:

Q6DHV7; A6NHZ3; B4DQM8

Background:

Adenosine deaminase-like protein, also known as N6-mAMP deaminase, plays a crucial role in the metabolism of methylated adenosine nucleotides. It catalyzes the hydrolysis of N(6)-methyl-AMP to inositol monophosphate and methylamine, facilitating the catabolism of cytosolic N6-mAMP derived from m6A-containing mRNA degradation. This enzyme also acts on various alkyl groups from N6-substituted purine or 2-aminopurine nucleoside monophosphates and O6-substituted compounds.

Therapeutic significance:

Understanding the role of Adenosine deaminase-like protein could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.